Nuo Therapeutics Posts $2.5M Net Loss in 2025 10-K, Revenue Reaches $3.3M
Summary
Nuo Therapeutics filed its 2025 10-K, reporting total revenues of $3.3 million, driven by a 126% year-over-year increase in product sales, but also a net loss of $2.5 million for the year. Despite revenue growth, the company's aggregate gross margin declined to approximately 67% from 78% in 2024, and operating expenses rose significantly. The substantial net loss indicates ongoing profitability challenges, which is a material concern for investors. Traders will be closely monitoring management's commercial strategy, including strengthening distributor relationships and increasing reimbursement awareness, to evaluate the company's path to sustainable profitability.
At the time of this announcement, AURX was trading at $1.44 on OTC in the Life Sciences sector, with a market capitalization of approximately $69.2M. The 52-week trading range was $0.71 to $3.23. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.